Cardiac resynchronization therapy (CRT) has been
shown to have clinical benefits in certain groups of
patients with advanced heart failure (HF). However,
patients with valvular cardiomyopathy are
underrepresented in randomized clinical studies. The aim
of this study was to assess the medium-term (i.e., at 6
months) effects of CRT in patients with HF exclusively
due to valvular disease. The study included 40
consecutive patients who underwent CRT device
implantation. At 6 months, there were improvements in
functional class, left ventricular remodeling, and
intraventricular dyssynchrony parameters in treated
patients. In this particular subgroup of patients, the
benefits of CRT were similar to those observed in patients
with HF due to other etiologies
